

INTERNATIONAL HEALTHTEC SUMMIT 2025

23-25 JULY 2025



CONFERENCE E-BOOKLET

TABLE OF CONTENT

03

Director's Foreword

32

Programme Details
24 JULY 2025

04

About

48

Programme Details
25 JULY 2025

06

Programme at a Glance

54

Acknowledgements

15

Programme Details
23 JULY 2025



DIRECTOR'S FOREWORD



A/Prof Ali Asgar S. Bhagat

Director, Singapore Health
Technologies Consortium
(HealthTEC.SG)

International HealthTEC
Summit 2025

It is both an honour and a privilege to welcome you to the International HealthTEC Summit (IHS) 2025.

Following the resounding success of our inaugural International HealthTEC Week in 2024 - which convened over 350 esteemed stakeholders across academia, industry, and healthcare - we return this year with expanded ambition and deeper regional engagement. Building on this momentum, IHS 2025 affirms our continued dedication to advancing innovation, collaboration, and real-world impact across the health technology landscape.

Set in Singapore - Asia's leading innovation and biomedical hub - IHS 2025 serves as a vital platform for shaping the future of healthcare technologies in the Asia-Pacific region and beyond. The theme of this year's summit, "Innovating the Future of Health Technologies," captures our collective mission: to not only explore groundbreaking advancements, but to tackle the practical challenges of implementation, accessibility, and scalability in diverse healthcare settings.

Our thoughtfully curated programme addresses the most dynamic frontiers in the field—from the promise of Precision Health and the rapid evolution of FemTech, to technologies enabling Ageing and Longevity. These focus areas are more than timely; they are essential to understanding and designing the next generation of healthcare solutions in a rapidly changing world.

Key highlights of IHS 2025 include HealthTech Pitch Asia, a showcase for emerging ventures driving the next wave of healthcare innovation, and the Singapore edition of the Sahlgrenska Global Health Hackathon, a collaborative forum for developing actionable solutions at the intersection of technology and health. These initiatives embody our ethos: to transform bold ideas into measurable outcomes through cross-disciplinary partnership and entrepreneurial energy.

Leading the Singapore Health Technologies Consortium (HealthTEC.SG) over the past year has been a distinct privilege. I have witnessed firsthand the growing vibrancy of the global HealthTech ecosystem—marked by accelerating digital transformation, the convergence of AI and life sciences, and an increasing emphasis on patient-centric, value-based care. Amidst these global shifts, Singapore stands uniquely positioned. With its strong regulatory infrastructure, translational research capacity, and strategic connectivity, Singapore is not only a testbed for innovation but a gateway to scaling health technologies across the broader Asia-Pacific region.

At its core, IHS 2025 is anchored in the belief that the future of healthcare will be co-created—by scientists, engineers, clinicians, entrepreneurs, and policymakers—united in purpose and action. I encourage you to participate actively: challenge ideas, form new collaborations, and help shape solutions that are as inclusive as they are innovative.

Together, let us accelerate the journey toward a smarter, healthier, and more equitable future.



ABOUT

ABOUT INTERNATIONAL HEALTHTEC SUMMIT 2025

International HealthTEC Summit (IHS) 2025 is a premier three-day event spotlighting the latest advancements in healthcare technology across Singapore and the Asia-Pacific region. Organized by the Singapore Health Technologies Consortium (HealthTEC.SG) and set in the vibrant city of Singapore, IHS 2025 serves as a central platform for knowledge exchange, innovation, and strategic networking. Building on the success of the inaugural International HealthTEC Week 2024, which welcomed over 350 participants from academia, industry, and healthcare sectors across the region, IHS 2025 is poised to expand its impact and reach.

This year's theme, "Innovating the Future of Health Technologies" explores emerging and future trends, and implementation challenges shaping the Asia-Pacific healthcare innovation landscape. The programme delves into the evolving domains of Precision Health and FemTech, and features a dedicated symposium on technologies for Ageing and Longevity. Participants will gain insights into Singapore's MedTech development and manufacturing ecosystem, and have the opportunity to take part in HealthTech Pitch Asia—a dynamic pitching event that seeks innovative solutions to real-world corporate healthcare challenges. IHS 2025 will also host the Singapore edition of the Sahlgrenska Global Health Hackathon, promoting collaborative approaches to tackling global health issues.

Bringing together a diverse ecosystem of researchers, innovators, healthcare providers, multinational corporations, and government agencies, IHS 2025 aims to spark meaningful dialogue and partnerships that will redefine the future of healthcare delivery in the region and beyond.

UNITING INDUSTRY AND ACADEMIA AT HEALTHTEC.SG



Funded by the National Research Foundation (NRF), the Singapore Health Technologies Consortium (HealthTEC.SG) is a technology consortium hosted by the Consortium Management Office (CMO) at Agency for Science, Technology and Research (A*STAR). HealthTEC.SG seeks to develop the health technology ecosystem, focusing on both software- and hardware-based health technologies that aims to transform health and wellness. Through facilitating partnerships across academia, industry and healthcare institutions, the Consortium accelerates the adoption and value capture of technologies developed in the research ecosystem for the industry. To enhance synergies among ecosystem stakeholders for innovation opportunities, HealthTEC.SG organises health technology symposia, seminars, and workshops regularly for their members, and collaborates actively with overseas ecosystems to promote cross-market academic-industry R&D partnerships that may lead to relevant industry outcomes.

ABOUT

ORGANISING COMMITTEE



A/Prof Ali Asgar S. Bhagat

Director,
Singapore Health Technologies
Consortium (HealthTEC.SG)



Dr Gordon Xiong

Senior Assistant Director,
Singapore Health Technologies
Consortium (HealthTEC.SG)



Ms Eliza Ho Pei Xin

Senior Manager,
Singapore Health Technologies
Consortium (HealthTEC.SG)



Mr Sheam Kannan

Manager,
Singapore Health Technologies
Consortium (HealthTEC.SG)



Ms Harini Narasa

Executive, Singapore Health
Technologies Consortium
(HealthTEC.SG)



PROGRAMME AT A GLANCE

23 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Level 6 Grand Ballroom, One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562

Time	Programme
0830 - 0900	Registration
0900 - 0910	WELCOME ADDRESS Dr Gordon Xiong Senior Assistant Director, Singapore Health Technologies Consortium (HealthTEC.SG)
0910 - 0940	PLENARY LECTURE Managing Aging Successfully, as a Society and Economy, with Technology Dr Cheong Wei Yang Vice Provost, Strategic Research Partnerships, Singapore Management University
0940 - 1015	KEYNOTE LECTURE Precision Health in Cohort Studies Prof Johan Gunnar Eriksson Executive Director, Institute for Human Development and Potential (IHDP), A*STAR
1015 - 1040	SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE? Interaction of Transformation and Innovation in Healthcare Ms Chee Hew Director, Medtech Key Account, Clearstate
1040 - 1110	Morning Tea Break

PROGRAMME AT A GLANCE

23 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Level 6 Grand Ballroom, One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562

Time	Programme
1110 – 1210	<p>SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE? Panel Discussion</p> <p>Moderator: A/Prof Ali Asgar Saleem Bhagat Director, Singapore Health Technologies Consortium (HealthTEC.SG)</p> <p>Panelists: Dr Cheong Wei Yang Vice Provost, Strategic Research Partnerships, Singapore Management University</p> <p>Prof Johan Gunnar Eriksson Executive Director, Institute for Human Development and Potential (IHDP), A*STAR</p> <p>Mr Ambuj Mudgal Senior Director, Commercial IT and Digital, Asia IT, AstraZeneca</p> <p>Mr Surajkumar Chandrasekharan Senior Vice President, Head of Diagnostic Imaging – ASEAN, Siemens Healthineers</p>
1210 - 1300	<p>SESSION: HEALTHTEC.SG - IPI PANEL: OPPORTUNITIES AND CHALLENGES FOR FEMTECH IN ASIA PACIFIC Panel Discussion</p> <p>Moderator: Ms Eunice Soh Senior Manager, Innovation Partner for Impact (IPI), Singapore</p> <p>Panelists: Dr Ella Fung Co-Founder & Chief Executive Officer, Rosalind Dx</p> <p>Mr Amrish Nair Co-Founder, Biorithm</p> <p>Ms Mairin Reid Head of Technology, IQVIA; Co-Founder, Cogniant</p>



PROGRAMME AT A GLANCE

23 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Level 6 Grand Ballroom, One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562

Time	Programme
1300 - 1310	Sharing by Design Singapore Council Mr Jeff Chia Senior Assistant Director, Partners and International Relations, Design Singapore Council
1310 - 1320	Sharing by Hong Kong Science and Technology Park Ms Priscilla Chiu Associate Director, New Ventures Development (Life and Health Technology), Hong Kong Science and Technology Parks Corporation
1320 - 1420	Lunch
1420 - 1430	HEALTHTECH PITCH ASIA Introduction
1430 - 1505	HEALTHTECH PITCH ASIA Murata Challenge Statement Sharing & Pitching  Challenge Statement: Non-Invasive Technologies for Early Mobility Health Intervention
1505 - 1640	HEALTHTECH PITCH ASIA Roche Challenge Statement Sharing & Pitching  Challenge Statement 1: Early Detection of Cognitive Decline (MCI/AD) Challenge Statement 2: Data driven Diagnostics and Risk Stratification Challenge Statement 3: Lab Automation and Operational Efficiency
1640 - 1655	HEALTHTECH PITCH ASIA Closing
1655 - 1730	Afternoon Tea & Networking
End of Day 1 Programme	

PROGRAMME AT A GLANCE

24 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Clinical Research Centre Auditorium (CRC) Level 1, Block MD11, 10 Medical Drive, Yong Loo Lin School of Medicine, Singapore 117597

Time	Programme
0830 - 0900	Registration
0900 - 0945	<p>PLENARY LECTURE Building a Collaborative Clinical Research Ecosystem: The role of CRIS</p> <p>A/Prof Danny Soon Chief Executive Officer, Consortium for Clinical Research and Innovation, Singapore (CRIS)</p>
0945 - 1030	<p>KEYNOTE LECTURE Wearable Assistive Robots for Aging Society</p> <p>Prof Ning Xi Director, Advanced Technologies Institute, The University of Hong Kong</p>
1030 - 1100	Morning Tea Break
1100 - 1130	<p>SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING Optimizing the Trajectory of Aging: Precision Geromedicine</p> <p>Prof Andrea B. Maier Co-Founder, NUS Academy for Healthy Longevity, National University of Singapore</p>
1130 - 1200	<p>SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING Digital-Facilitated Healthy Ageing Interventions for Chronic Disease Management Among Older Adults and Caregivers: Translating Research into Practice</p> <p>Dr Wu Xi Vivien Assistant Professor, Alice Lee Centre for Nursing Studies, National University of Singapore</p>
1200 - 1210	<p>Sharing by NUS DATA</p> <p>Mr Aristotle Ang General Manager, Digital Advanced Technology Accelerator, Yong Loo Lin School of Medicine, National University of Singapore</p>

PROGRAMME AT A GLANCE

24 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Clinical Research Centre Auditorium (CRC) Level 1, Block MD11, 10 Medical Drive, Yong Loo Lin School of Medicine, Singapore 117597

Time	Programme
1210 - 1220	<p>Sharing by FeM Surgery</p> <p>Ms Tiziana Tan General Manager, Digital Advanced Technology Accelerator, Yong Loo Lin School of Medicine, National University of Singapore</p>
1220 - 1350	Lunch
1350 - 1435	<p>KEYNOTE LECTURE Primum Non Nocere, Secundum Simulare: The imperatives of in silico evidence in the digital era</p> <p>Prof Alejandro F Frangi Bicentenary Turing Chair in Computational Medicine, University of Manchester, Manchester, United Kingdom</p>
1435 - 1505	<p>SESSION: ADVANCING HEALTH THROUGH DIGITAL INNOVATIONS Use of AI Algorithm for Infant Growth Measurements</p> <p>Ms Agathe Foussat Director of Digital Health, Danone Asia Pacific</p>
1505 - 1535	<p>SESSION: ADVANCING HEALTH THROUGH DIGITAL INNOVATIONS Hyper-personalized Digital Twins for Early Pre-diabetes Interception</p> <p>Dr James Chan Deputy Head of Division, Nutrition & Digestive Health, Singapore Institute of Food and Biotechnology Innovation (SIFBI), A*STAR</p>
1535 - 1605	Afternoon Tea Break

PROGRAMME AT A GLANCE

24 JULY 2025

Time: 0830 - 1700 SGT (GMT+8)

Venue: Clinical Research Centre Auditorium (CRC) Level 1, Block MD11, 10 Medical Drive, Yong Loo Lin School of Medicine, Singapore 117597

Time	Programme
1605 - 1700	<p>SESSION: INTRODUCTION TO MEDICAL DEVICES ECOSYSTEM IN SINGAPORE: MEDTECH CATAPULT & DIGITAL HEALTH ACCELERATOR INITIATIVES</p> <p>Panel Discussion</p> <p>Moderator: Dr Gordon Xiong Senior Assistant Director, Singapore Health Technologies Consortium (HealthTEC.SG)</p> <p>Panelists: Mr Justin Phoon Lead, Programme & Partnerships, MedTech Catapult</p> <p>Mr Lijoy George Head of Digital Diagnostics, Lead of Digital Health Accelerator, DxD Hub</p> <p>Mr Edwyn Tan Sales Director Asia, Cicor Group</p>
1700 - 1900	<p>Tour of MedTech Catapult Facilities (Limited Capacity)</p> <p>Venue: MedTech Catapult, Biopolis</p>
End of Day 2 Programme	

PROGRAMME AT A GLANCE

25 JULY 2025

Time: 1000 - 1200 SGT (GMT+8)

Venue: Catapult by CapitalLand, 1 Rochester Park #02-01 Rochester Commons, Singapore, 139212

Time	Programme
1000 - 1020	Registration
1020 - 1030	<p>WELCOME & OPENING REMARKS</p> <p>Mr Chris Lee Founder & CEO, VentureBlick</p> <p>Dr Gordon Xiong Senior Assistant Director, Singapore Health Technologies Consortium (HealthTEC.SG)</p>
1030 - 1035	<p>MEET THE JUDGES</p> <p>Judges:</p> <p>Mr Chris Lee Founder & CEO, VentureBlick</p> <p>Ms Jennifer Cho Senior Vice President and General Manager, Dexcom APAC</p> <p>Mr Gang Chern Sun Programme Director, Korea SMEs & Startups Agency (KOSME), Singapore</p> <p>Mr Karunan Gunasekaran Assistant Vice President, Corporate Venture Capital, IHH Healthcare</p>
1035 - 1125	<p>STARTUP SHOWCASE: FEATURING HEALTHCARE INNOVATORS FROM KOREA Live Pitch and Judges' Q&A</p> <p>Participating Startups:</p> <p>Medicos Biotech: Producing spider silk protein at scale using E. coli for wound care, cosmetics, and skin regeneration.</p> <p>IMBdx: Liquid biopsy technologies for early cancer detection, precision diagnosis, and personalised therapy.</p> <p>(continued on next page)</p>



PROGRAMME AT A GLANCE

25 JULY 2025

Time: 1000 - 1200 SGT (GMT+8)

Venue: Catapult by CapitalLand, 1 Rochester Park #02-01 Rochester Commons, Singapore, 139212

Time	Programme
	<p>MediIMG: 3D full-colour cerebral vessel models that serve as novel biomarkers for stroke and neurovascular diagnostics.</p> <p>Ezdiagtech: A magnetic particle-based fluorescent imaging system enabling ultra-sensitive, multiplexed diagnostics for sepsis and brain injuries.</p> <p>Onesoftdigm: Smart health devices that track body metrics to deliver personalised insights and predict diabetes risk.</p> <p>NetTargets: AI-driven systems biology for faster, smarter drug discovery</p> <p>Twinpig Biolab: Peptide-drug conjugates targeting tumour environments</p> <p>AttisLab: Cell therapies for hair growth, anti-aging, and tissue repair</p>
1125 - 1140	<p>ANNOUNCEMENT OF WINNERS Audience Voting Score Tabulation Judges' Comments Announcement of Winners</p>
1140 - 1200	Refreshment and Networking
End of Day 3 Morning Programme	

PROGRAMME AT A GLANCE

25 JULY 2025

Time: 1400 - 1900 SGT (GMT+8)

Venue: SGIInnovate, 32 Carpenter St, Singapore 059911

Time	Programme
1400 - 1430	Registration
1430 - 1500	<p>EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR Sharing by SGIInnovate</p> <p>Dr Vanessa Ding Deputy Director, Talent, SGIInnovate</p>
1500 - 1530	<p>EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR Sharing by AstraZeneca</p> <p>Mr Samuel Koh Corporate Affairs Director, AstraZeneca Singapore</p>
1530 - 1600	<p>EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR Sharing by Enterprise Singapore</p> <p>Mr Jerrold Chua Senior Development Partner, Global Innovation Network, Enterprise Singapore</p>
1600 - 1730	<p>SAHLGRENKA GLOBAL HEALTH HACKATHON-SINGAPORE LEG Introduction to Sahlgrenska Science Park Presentation by the top 3 finalists of the Sahlgrenska Global Health Hackathon Announcement of the Singapore leg winner</p> <p>Ms Cecilia Edebo CEO, Sahlgrenska Science Park</p>
1730 - 1900	Networking Reception
End of Day 3 Afternoon Programme	

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 0900 – 0910

WELCOME REMARKS

SPEAKER'S PROFILE



Dr Gordon Xiong

Senior Assistant Director, Singapore Health Technologies Consortium
(HealthTEC.SG)

Dr. Gordon Xiong is the Senior Assistant Director of the Singapore Health Technologies Consortium (HealthTEC.SG). He has around 15 years of experience in R&D and managing innovation in health-related fields. In his current role, he oversees the planning and execution of the Consortium's ecosystem-building initiatives, including industry development, innovation partnerships and community-building events. Prior to his current role, he has worked as a researcher and laboratory manager in several disciplines of molecular biology and bioengineering and held the roles of co-investigator or theme lead of projects. He has published 30 peer-reviewed journal articles/reviews/book chapters and holds 3 patent applications, including one granted patent.

Passionate in contributing to the healthcare and biomedical engineering community, he currently serves as the Vice-President of the Biomedical Engineering Society (Singapore), as a Member of the Biomedical and Health Standards Committee (BHSC) of the Singapore Standards Council and is active in mentoring young entrepreneurs and global young fellows on innovation.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 0910 – 0940

PLENARY LECTURE

Managing Aging Successfully, as a Society and Economy, with Technology

SYNOPSIS

Societies are aging rapidly—not only in Singapore, but also in major cities across Asia. The urban setting, blessed with rapid digitalisation, provides an opportune environment to deploy technology in novel and unprecedented ways, to harvest new value from our aging populations and relieve the burden on younger populations, so that our society and economy can continue to thrive despite an aging population. Within this construct, population health, precision health, and preventive health will play an important role, with digitalised HealthTech being one of the key enablers.

SPEAKER'S PROFILE



Dr Cheong Wei Yang

Vice Provost, Strategic Research Partnerships, Singapore Management University

Senior Adviser (Health Economics), Ministry of Health (MOH), Singapore

Dr Cheong is Vice Provost for Strategic Research Partnerships in Singapore Management University, and concurrently Senior Adviser for Health Economics at MOH, and Chair of the Board Oversight Committee of Advanced Cell Therapy and Research Institute of Singapore (ACTRIS).

Previously, as Deputy Secretary (Technology) at MOH, Dr Cheong deployed technology against COVID-19 and developed the health research and innovation ecosystem to achieve Healthier SG – i.e. population health, precision health and preventive health. He also sat on the Board of Integrated Health Information Systems (IHIS), which has since been renamed as Synapse.

Prior to MOH, he was Deputy CEO of National Research Foundation (NRF), where he oversaw the implementation of the S\$19 billion Research Innovation and Enterprise (RIE) 2020 plan and led an inter-agency effort to develop the S\$25 billion RIE 2025 plan.

(continued on next page)



PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 0910 – 0940

PLENARY LECTURE

[Managing Aging Successfully, as a Society and Economy, with Technology](#)

Dr Cheong was also Divisional Director (Planning) in MOE. Beyond educational policies, he shaped educational research at National Institute of Education, international benchmarking and partnership efforts. As Deputy Director (Manufacturing & Services) at MTI, he oversaw EDB, and the Secretariat for Economic Strategies Committee chaired by Senior Minister Tharman Shanmugaratnam. As Head Fiscal Strategy at Ministry of Finance, he shaped Singapore's long-term fiscal sustainability.

He served on the Boards of URA; ISEAS-Yusof Ishak Institute; NMRC; EDDC; DxD Hub; National Additive Manufacturing Programme; Singapore Food Story R&D Programme and NRF Holdings. He was also on the Boards of Centre for Research & Development in Learning (CRADLE), National Clinical Trial Steering Committee (NCTSC) and Precision Health Research Singapore (PRECISE).

As a Rhodes Scholar and PSC Scholar, he obtained his DPhil/Mphil in Economics from Oxford, and his S.B. in Chemical Engineering and S.B. in Economics from Massachusetts Institute of Technology.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 0940 – 1015

KEYNOTE LECTURE

Precision Health in Cohort Studies

SYNOPSIS

Precision health in cohort studies refers to the approach of combining deeply phenotyped cohort data (e.g. clinical, lifestyle, behavioral and environmental data) with advanced analytics (e.g. omics data). This approach enables us to tailor a proactive and personalized approach to disease prevention, as well as it allows for a more nuanced understanding of diseases.

There is a need to make precision health more equitable and more relevant for the Asian region by focusing on the unique Asian phenotype. This will be illustrated by examples from Asian cohorts in relation to major non-communicable diseases.

SPEAKER'S PROFILE



Prof Johan Gunnar Eriksson

Professor, Department of Obstetrics and Gynaecology
Programme Director, Human Potential Translational Research
Programme (HPTRP)
Yong Loo Lin School of Medicine, National University of Singapore
Executive Director, Institute for Human Development and Potential
(IHDP), A*STAR

Professor Johan G. Eriksson is professor at the NUS Yong Loo Lin School of Medicine, programme lead for the Human Potential Programme at the SOM, executive director at A*STAR Institute for Human Development and Potential (IHDP). He is in charge of the daily scientific oversight and planning of the GUSTO and S-PRESTO cohort studies as well as upcoming programmes focusing on adolescent health and wellbeing.

Before moving to Singapore professor Eriksson was full professor at the faculty of medicine, University of Helsinki, and chief physician at Helsinki University Hospital in Finland. He holds clinical interests in diabetes, obesity and related metabolic diseases. He received his medical degree and specialist qualifications (internal medicine and general practice) from the University of Helsinki.

(continued on next page)

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 0940 – 1015

KEYNOTE LECTURE

Precision Health in Cohort Studies

His research focuses on the early programming of health and disease, as well as on the prevention of gestational diabetes (GDM), type 2 diabetes and related metabolic outcomes by lifestyle interventions. In Finland he is in charge of the Helsinki Birth Cohort Study, a unique birth cohort study with a follow-up of over 20,000 individuals from birth until the age of over 80 years. Furthermore, he has been in the Finnish Diabetes Prevention Study (DPS) – the first randomised study to show that lifestyle intervention is effective in the prevention of type 2 diabetes cited over 8000 times.

He has published over 1000 original peer-reviewed research articles, many book chapters and received several scientific awards. He has been recognized and ranked as No 1 Scientist in the field of Medicine in Singapore in 2024 by Research.com.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1015 – 1040

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Interaction of Transformation and Innovation in Healthcare

SYNOPSIS

Healthcare is evolving in Asia Pacific with key trends such as decentralized care delivery, expansion of service providers across clinical pathway. This is also a shift towards preventive healthcare through advanced diagnostics such as diabetes, cancer and cardiovascular conditions due to high costs in treatment. It is also key to highlight that transformation via technology is also rising, with automation increasingly in demand with AI following up slowly via private public partnerships

SPEAKER'S PROFILE



Ms Chee Hew

Director, Medtech Key Account, Clearstate

Chee Hew is an experienced consultant in the healthcare and life sciences sector in North America and Asia Pacific, with extensive experience in business and operational strategy consulting, leveraging strong market research capabilities. She brings 25 years of healthcare experience in Asia Pacific particularly in China.

Prior to joining Clearstate, Chee was the Strategy & Change Pharmaceutical leader in IBM Global Business Services (previously PricewaterhouseCoopers) in China. Before that, she was with the North American R&D pharmaceutical industry practice based in Toronto. Chee has extensive experience working with senior executives of both healthcare and life sciences companies and government organizations to develop and implement strategic plans. Chee has managed large scale and multiple year projects to provide credible market insights to help clients achieve sustainable growth. She has led numerous consulting projects to formulate winning go-to-market strategies in emerging markets in Asia Pacific, Europe and Latin America.

(continued on next page)



PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1015 – 1040

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

[Interaction of Transformation and Innovation in Healthcare](#)

At Clearstate, Chee collaborates extensively with leading medtech clients such as Roche, Abbott, Sysmex, Danaher and Johnson & Johnson globally. She focuses on their data insights needs for both developed and emerging countries, and has provided strategic insights to help guide their future growth.

She has also published various white papers and presented at major conferences on current healthcare topics in Asia. She has covered topics such as “Future Outlook for Health in China”, “SE Asia: The New Emerging Healthcare Market Challenge”, etc.

Chee holds an MBA from Schulich School of Business, York University (Canada) and BSc (Hons) in Microbiology from University of Toronto.



PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1110 – 1210

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Panel Discussion

SYNOPSIS

As we look toward 2040, precision health promises to redefine the future of care—shifting from reactive treatment to proactive, personalized, and predictive healthcare. But are we truly ready for this revolution?

This panel brings together leading voices from policy, academia, and industry to envision a future where genomics, AI, digital diagnostics, and behavioral insights converge to shape the patient journey from prevention to treatment.

Join us for a dynamic, cross-sector dialogue that examines not just the promise of precision health, but the practical readiness—technological, regulatory, and cultural—needed to make it a regional reality. Expect sharp insights, healthy debate, and actionable ideas for Singapore and APAC to lead the charge toward a more precise, people-centered health future.

SPEAKERS' PROFILE

MODERATOR



A/Prof Ali Asgar S. Bhagat

Director, Singapore Health Technologies Consortium (HealthTEC.SG)

Dr. Ali Asgar Bhagat is the Director of the Singapore Health Technologies Consortium (HealthTEC.SG) and Deputy Director (Translation) at the Institute for Health Innovation and Technology (iHealthtech) and Associate Professor (Practice) in the Department of Biomedical Engineering at National University of Singapore.

(continued on next page)

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1110 – 1210

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Panel Discussion

He leads the translation arm of iHealthtech, Healthtech Translation Hub (HATCH), overseeing intellectual property filing, technology development and commercialization, and developing strategic programs to promote the Institute's mission. Before NUS, A/Prof. Bhagat was Principal Manager at Accelerate Technologies Pte Ltd, the commercialization arm of Agency for Science, Technology and Research (A*STAR), in-charge of evaluation and commercialization of biomedical (life sciences and medical device) research output of multiple institutes (>100 patent families). He was also the Chief Operating Officer (COO) of Clearbridge Biomedics Pte Ltd (now Biolidics Ltd), a NUS spin-off developing novel oncology diagnostic solutions. At Clearbridge, he led the Research and Innovation department overseeing the development of ClearCell® line of products from concept to commercial launch. Before joining Clearbridge, he worked as Research Scientist in Biosystems and Micromechanics (BioSyM) group at the Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore.

A/Prof. Ali Asgar Bhagat received his MS (2006) and PhD (2009) in Electrical Engineering from the University of Cincinnati, USA and held Associate Scientist position at Massachusetts Institute of Technology (MIT), USA.

PANELISTS



Dr Cheong Wei Yang

Vice Provost, Strategic Research Partnerships, Singapore Management University

Senior Adviser (Health Economics), Ministry of Health (MOH), Singapore

Dr Cheong is Vice Provost for Strategic Research Partnerships in Singapore Management University, and concurrently Senior Adviser for Health Economics at MOH, and Chair of the Board Oversight Committee of Advanced Cell Therapy and Research Institute of Singapore (ACTRIS).

Previously, as Deputy Secretary (Technology) at MOH, Dr Cheong deployed technology against COVID-19 and developed the health research and innovation ecosystem to achieve Healthier SG – i.e. population health, precision health and preventive health. He also sat on the Board of Integrated Health Information Systems (IHIS), which has since been renamed as Synapxe.

(continued on next page)

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1110 – 1210

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Panel Discussion

Prior to MOH, he was Deputy CEO of National Research Foundation (NRF), where he oversaw the implementation of the S\$19 billion Research Innovation and Enterprise (RIE) 2020 plan and led an inter-agency effort to develop the S\$25 billion RIE 2025 plan.

Dr Cheong was also Divisional Director (Planning) in MOE. Beyond educational policies, he shaped educational research at National Institute of Education, international benchmarking and partnership efforts. As Deputy Director (Manufacturing & Services) at MTI, he oversaw EDB, and the Secretariat for Economic Strategies Committee chaired by Senior Minister Tharman Shanmugaratnam. As Head Fiscal Strategy at Ministry of Finance, he shaped Singapore's long-term fiscal sustainability.

He served on the Boards of URA; ISEAS-Yusof Ishak Institute; NMRC; EDDC; DxD Hub; National Additive Manufacturing Programme; Singapore Food Story R&D Programme and NRF Holdings. He was also on the Boards of Centre for Research & Development in Learning (CRADLE), National Clinical Trial Steering Committee (NCTSC) and Precision Health Research Singapore (PRECISE).

As a Rhodes Scholar and PSC Scholar, he obtained his DPhil/Mphil in Economics from Oxford, and his S.B. in Chemical Engineering and S.B. in Economics from Massachusetts Institute of Technology.



Prof Johan Gunnar Eriksson

Professor, Department of Obstetrics and Gynaecology
Programme Director, Human Potential Translational Research
Programme (HPTRP)

Yong Loo Lin School of Medicine, National University of Singapore
Executive Director, Institute for Human Development and Potential
(IHDP), A*STAR

Professor Johan G. Eriksson is professor at the NUS Yong Loo Lin School of Medicine, programme lead for the Human Potential Programme at the SOM, executive director at A*STAR Institute for Human Development and Potential (IHDP). He is in charge of the daily scientific oversight and planning of the GUSTO and S-PRESTO cohort studies as well as upcoming programmes focusing on adolescent health and wellbeing.

(continued on next page)

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1110 – 1210

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Panel Discussion

Before moving to Singapore professor Eriksson was full professor at the faculty of medicine, University of Helsinki, and chief physician at Helsinki University Hospital in Finland. He holds clinical interests in diabetes, obesity and related metabolic diseases. He received his medical degree and specialist qualifications (internal medicine and general practice) from the University of Helsinki.

His research focuses on the early programming of health and disease, as well as on the prevention of gestational diabetes (GDM), type 2 diabetes and related metabolic outcomes by lifestyle interventions. In Finland he is in charge of the Helsinki Birth Cohort Study, a unique birth cohort study with a follow-up of over 20,000 individuals from birth until the age of over 80 years. Furthermore, he has been in the Finnish Diabetes Prevention Study (DPS) – the first randomised study to show that lifestyle intervention is effective in the prevention of type 2 diabetes cited over 8000 times.

He has published over 1000 original peer-reviewed research articles, many book chapters and received several scientific awards. He has been recognized and ranked as No 1 Scientist in the field of Medicine in Singapore in 2024 by Research.com.



Mr Ambuj Mudgal

Senior Director, Commercial IT and Digital, Asia IT, AstraZeneca

Ambuj brings over 19 years of global experience in digital transformation, AI, and Healthtech. He has held IT and digital leadership roles at organizations including AstraZeneca, Teva Pharmaceuticals, Amazon, Abbott, Medtronic, and Sanofi, leading initiatives aimed at improving patient outcomes and operational efficiency.

He has worked closely with healthtech startups and government institutions on projects involving data sharing, technology enablement for screening and diagnostics, and support for large-scale studies.

His work spans both commercial and Healthtech domains, with a focus on building / supporting practical, accessible and scalable digital solutions.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1110 – 1210

SESSION: PRECISION HEALTH IN 2040: ARE WE READY FOR A REVOLUTION IN HEALTHCARE?

Panel Discussion



Mr Surajkumar Chandrasekharan

Senior Vice President, Head of Diagnostic Imaging – ASEAN
Siemens Healthineers

Surajkumar Chandrasekharan has accumulated over 30 years of global leadership in the Medtech industry. As Senior Vice President and Head of Diagnostic Imaging for ASEAN at Siemens Healthineers, he brings a wealth of experience in driving operational excellence and strategic growth across diverse healthcare markets.

Known for his multicultural perspective and results-driven leadership, Surajkumar has led high-performing teams and delivered impactful outcomes in diagnostic imaging. His strengths lie in aligning strategy with execution, enabling innovation, and fostering collaboration to meet evolving healthcare needs.

He holds an Executive MBA from ESMT Berlin and a Bachelor of Technology in Electronics from the University of Kerala - credentials that complement his deep industry expertise and technological insight.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1210 – 1300

SESSION: HEALTHTEC.SG - IPI PANEL: OPPORTUNITIES AND CHALLENGES FOR FEMTECH IN ASIA PACIFIC

Panel Discussion

SYNOPSIS

The Asia Pacific region is emerging as a dynamic hub for FemTech, driven by increasing digital health adoption, and a growing demand for personalized healthcare solutions. Countries like Singapore, India, and Indonesia are witnessing a surge in FemTech startups, focusing on areas such as reproductive health and maternal care. However, the sector faces challenges including regulatory complexities, limited funding opportunities and targeted collaboration partners. This panel will delve into the evolving landscape of FemTech in Asia Pacific, exploring the opportunities for innovation and the hurdles that need to be addressed to foster sustainable growth and inclusivity in women's health technology.

SPEAKERS' PROFILE

MODERATOR



Ms Eunice Soh

Senior Manager, Innovation Partner for Impact (IPI), Singapore

Eunice currently serves as an Innovation Advisory and Technology Senior Manager at IPI, a subsidiary of Enterprise Singapore. Eunice works closely with healthcare and consumer companies to understand their needs, map out business gaps, and recommend technology-driven strategies including commercialization, adoption and providing advisory. Over her time in IPI, Eunice has managed technology partnering and advisory projects for various profiles of companies helping to accelerate and forge collaboration locally and with overseas ecosystem partners to drive transformation and business opportunities. Prior to IPI, Eunice is senior manager with Chugai Pharmaceuticals specialising in proprietary antibody technologies for biologics drug development. Eunice is passionate about overcoming constraints in the healthcare space and bridging resources to enable innovations to reach audiences.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1210 – 1300

SESSION: HEALTHTEC.SG - IPI PANEL: OPPORTUNITIES AND CHALLENGES FOR FEMTECH IN ASIA PACIFIC

Panel Discussion

PANELISTS



Dr Ella Fung

Co-Founder & Chief Executive Officer, Rosalind Dx

Dr. Ella Fung is the Co-Founder & CEO of Rosalind Dx. She has over 8 years of industry experience spanning both biopharma and diagnostics, specializing in molecular biology and target discovery. She has been an early employee at multiple life science startups in Boston and Singapore driving R&D strategy and IP generation and was a Postdoctoral Fellow at Pfizer (Boston). She holds a PhD in Oncology from the University of Oxford, an MS in Genetics from the Université Paris Diderot, and a BA (Hons) in Natural Sciences (Genetics) from the University of Cambridge.



Mr Amrish Nair

Co-Founder, Biorithm

Since graduating from NTU, Amrish has worked on medical technology solving problems in underserved areas such as women's health. He spun off Biorithm to improve access to health and end preventable poor outcomes in maternity care. He is surrounded by a great team at Biorithm and works with inspirational clinical leaders globally, who together are looking to solve hard problems in women's health.



PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1210 – 1300

SESSION: HEALTHTEC.SG - IPI PANEL: OPPORTUNITIES AND CHALLENGES FOR FEMTECH IN ASIA PACIFIC

Panel Discussion



Ms Mairin Reid

Head of Technology, IQVIA; Co-Founder Cogniant

Mairin Reid leads Commercial Tech, and Patient, Provider, and Government Technology at IQVIA across Southeast Asia and the APAC Regional Headquarters. With over 18 years of experience across pharma, medtech, and government sectors, she has led digital transformation, HCP engagement, and patient solutions globally. A former startup founder, Mairin is also an active angel investor and advisor to early-stage ventures in health and enterprise tech, with a strong focus on innovation in digital health and femtech.

PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1300 – 1310

SHARING BY DESIGN SINGAPORE COUNCIL

SPEAKER'S PROFILE



Mr Jeff Chia

Senior Assistant Director, Partners and International Relations, Design
Singapore Council

Jeff is the Senior Assistant Director at DesignSingapore Council, where he leads the Partners and International Relations team. In this role, he collaborates closely with industry leaders to drive design activity in Singapore while championing Singapore's design excellence on the global stage.

With a career spanning both business strategy and economic development, Jeff began as a Pricing Analyst at Cummins Inc. before joining the Singapore Economic Development Board (EDB). Over his seven-year tenure at EDB, he served as a Regional Director in the USA and contributed to the Semiconductors division. His efforts have played a pivotal role in attracting investments from leading companies such as Figma, SoftServe, and Zoom, while also securing reinvestments from industry giants including Alcon, AMD, Dell, Lucasfilm, HP, and Seagate.



PROGRAMME DETAILS

23 JUL 2025

23 JUL 2025 | 1310 - 1320

SHARING BY HONG KONG SCIENCE AND TECHNOLOGY PARK

SPEAKER'S PROFILE



Ms Priscilla Chiu

Associate Director, New Ventures Development (Life and Health Technology), Hong Kong Science and Technology Parks Corporation

Priscilla Chiu specializes in Life and Health Technology, focusing on New Venture Development at Hong Kong Science and Technology Parks Corporation (HKSTP). She actively collaborates with international biomedical technology hubs, life and health enterprises, and bio venture capital to facilitate global innovation exchange.

She oversees HKSTP's Soft Landing program in life and health sector, helping foreign biotech start-ups and enterprises establish Hong Kong as a strategic gateway for expansion into Southeast Asia and China.

Previously, she served as Business Unit Director at MSD Hong Kong & Macau and founded her own start-up, providing strategic guidance and advising healthcare organizations on business development and commercialization strategies.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 0900 – 0945

PLENARY LECTURE

Building a Collaborative Clinical Research Ecosystem: The role of CRIS

SYNOPSIS

We highlight the collaborative initiatives in clinical research and translation hosted and led by the Consortium for Clinical Research and Innovation Singapore (CRIS). This presentation will introduce CRIS's vision and its national clinical research programs, and turn the spotlight on 3 of our programmes. Efforts include regional clinical research networks, training and development unit for research study coordinators, centralised Clinical Trials Portal (CTSG), and national programs in cardiovascular and oncology fields. Biomedical research and translation play a key role in supporting Singapore's healthcare and economic agenda, and our programmes bring industry and academic collaborations together to achieve impactful outcomes.

SPEAKER'S PROFILE



A/Prof Danny Soon

Chief Executive Officer, Consortium for Clinical Research and Innovation, Singapore (CRIS)

Executive Director, Singapore Clinical Research Institute (SCRI)

Senior Advisor, Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

A/Prof Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI). Danny currently serves as Senior Advisor, Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) effective from 1 March 2025 to 31 August 2025. He was previously the Interim Executive Director of ACTRIS from 1 September 2022 to 28 February 2025. As the inaugural CEO of CRIS, Danny has the responsibility of bringing together six research programmes and platforms under the auspices of CRIS, promulgating synergies and strategies, building corporate functions to service the entire entity.

A/Prof Soon was previously the Executive Director of Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. A/Prof Soon also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre.

(continued on next page)

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 0900 – 0945

PLENARY LECTURE

Building a Collaborative Clinical Research Ecosystem: The role of CRIS

Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 0945 – 1030

KEYNOTE LECTURE

Wearable Assistive Robots for Aging Society

SYNOPSIS

A rapidly aging population is one of the grand challenges facing the society. The number of people aged 65 or older worldwide is estimated to reach 1.6 billion by 2050. A major difficulty that many older people experience is severe limitation in mobility and manipulability in their daily life, resulting in tremendous social and economic challenges. This talk will discuss a User-Centric Co-Creation (UC³) approach to develop intelligent robotic systems to assist mobility and manipulability. The UC³ methodology lays down a theoretical foundation for multi-disciplinary approach to develop personalized wearable assistive systems. It will pave a new avenue to advance the ergonomics and gerontechnology beyond current horizons.

SPEAKER'S PROFILE



Prof Ning Xi

Chair Professor, Robotics and Automation
Head of Department, Data and Systems Engineering
Director, Advanced Technologies Institute
The University of Hong Kong

Professor Ning Xi received D.Sc. degree in Systems Science and Mathematics from Washington University in St. Louis, Missouri, USA in December 1993. Currently he is the Chair Professor of Robotics and Automation and the Head of Department of Data and Systems Engineering of the University of Hong Kong, and Director of Advanced Technologies Institute. Before joining the University of Hong Kong, he was a University Distinguished Professor, the John D. Ryder Professor of Electrical and Computer Engineering and Director of Robotics and Automation Laboratory at Michigan State University in United States. He also served as the founding head of the Department of Mechanical and Biomedical Engineering at City University of Hong Kong (2011-2013). Prof. Xi is a fellow of IEEE. He also served as the President of IEEE Nanotechnology Council (2010-2011) and President of IEEE Robotics and Automation Society (2018). His research interests include robotics, manufacturing automation, micro/nano manufacturing, nano sensors and devices, and intelligent control and systems.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1100 – 1130

SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING

Optimizing the Trajectory of Aging: Precision Geromedicine

SYNOPSIS

Medical research has traditionally focused on disease mechanisms and therapies to restore health. This approach has been highly effective, but because of its effectiveness, demographics of countries are changing. Chronologic age is the largest risk factor for decline in organ function and for age-related diseases, which are now highly prevalent. Therewith, healthcare costs are steadily increasing and the gap between healthspan, the duration an individual maintains good health, and lifespan is escalating. The biological age of individuals can now be measured by use of biomarkers of ageing. Furthermore, geroprotective interventions are readily available to lower the biological age and therewith preventing age-related diseases and increasing healthspan. Geroprotectors include highly personalized lifestyle modifications, supplements and medication which are chosen based on the biological, clinical and digital phenotypes of individuals. Digital biomarkers of aging play a crucial role in edge evidence-based diagnostics and interventions of Precision Geromedicine, which are now being implemented into healthcare, to address the challenges of an ageing society.

SPEAKER'S PROFILE



Prof Andrea B. Maier

Oon Chiew Seng Professor in Medicine
Co-Founder, NUS Academy for Healthy Longevity
National University of Singapore
Professor of Gerontology, Vrije Universiteit Amsterdam, The Netherlands
Founder, Chi Longevity

Andrea B. Maier (1978), a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Director of the Centre for Healthy Longevity.

(continued on next page)

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1100 – 1130

SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING

Optimizing the Trajectory of Aging: Precision Geromedicine

Professor Maier's research focuses on unraveling the mechanisms of ageing and age-related diseases to bring diagnostics and interventions to optimize health into clinical practice. She is heading international longitudinal cohort studies and geroscience interventions. She has published more than 460 peer-reviewed articles, achieving an H index of 85, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs and book author to disseminate aging research. Furthermore, she is invited member and advisor of several international academic and health policy committees and funding agencies, including the World Health Organization evaluating the United Nations Decade of Healthy Ageing and Hevolution. In 2022, she co-founded the first evidence based Healthy Longevity Medicine Clinic in Singapore, Chi Longevity, and joined NU as Chief Medical Officer. She is the past President of The Australian and New Zealand Society for Sarcopenia and Frailty Research, the Founding President of the Healthy Longevity Medicine Society and serves as selected Member of The Royal Holland Society of Sciences and Humanities, Fellow of the Atria Academy of Science and Medicine, and Academy for Health and Lifespan Research. In 2023, she co-founded the NUS Academy for Healthy Longevity to disseminate Geroscience and evidence-based Precision Geromedicine.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1130 – 1200

SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING

Digital-Facilitated Healthy Ageing Interventions for Chronic Disease Management
Among Older Adults and Caregivers: Translating Research into Practice

SYNOPSIS

With one in four Singaporeans aged above 65 by 2030, promoting healthy ageing is imperative. Guided by the ageing trajectory model, our aim is to delay frailty and functional disability by enhancing the physical and cognitive function of community-dwelling older adults. We have introduced digital-facilitated interventions, including the Care4Senior app featuring health education, quizzes, cognitive games, and health-tracking tools; community dance program supported by wearable muscle oxygen sensors; and an AI-empowered platform that mobilises resources for older caregivers. Co-designed with clinicians, community eldercare practitioners, and government agencies, these scalable solutions translate research into real-world impact and support ageing-in-place within community.

SPEAKER'S PROFILE



Asst/Prof Vivien Wu

Assistant Professor, Alice Lee Centre for Nursing Studies, Yong Loo Lin
School of Medicine, National University of Singapore
Chair, Geriatric Care and Wellness Research Programme, NUS Nursing

Dr Vivien Wu Xi is an Assistant Professor at the Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore (NUS). She serves as the Chair of Healthy Ageing and Community Care Research Programme and is an active member of the Healthy Longevity Translational Research Program at NUS. Her work is at the forefront of healthy ageing research, with a dual focus on digital health interventions that empower older adults and caregivers in chronic disease management, and intergenerational programs that support ageing-in-place within the community.

(continued on next page)

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1130 – 1200

SESSION: INNOVATION FOR LONGEVITY: TECHNOLOGIES SHAPING THE FUTURE OF HEALTHY AGING

Digital-Facilitated Healthy Ageing Interventions for Chronic Disease Management
Among Older Adults and Caregivers: Translating Research into Practice

Dr Vivien's contributions have earned international recognition. She received the Emerging Nurse Researcher/Scholar Award from Sigma Theta Tau International in 2022, the Early Career Investigator Award by the Interstellar Initiative (New York Academy of Sciences and Japan AMED) and was named an Asian University Alliance Scholar in 2020. She was also honoured with the Exemplary Community Partner Award (2022) and listed among the World's Top 2% Most Cited Scientists by Stanford University and Elsevier in 2023 and 2024.

Her research is supported by competitive grants including the National Medical Research Council Clinician Scientist Award (NMRC Population Health, 2024), NMRC Population Health Research Grant (2023), NUHS Health Promotion Research Grant (2023), and international awards from the Japan Society for the Promotion of Science, among others. Her projects span digital health applications, intergenerational dance-based interventions, and brain health programs for older adults.

Dr Vivien holds a PhD from Jönköping University (Sweden), and advanced research training from University of Oxford (UK). A Registered Nurse under the Singapore Nursing Board, she also serves as editor and reviewer for leading international journals in nursing and medicine.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1200 – 1210

SHARING BY NUS DATA

SPEAKER'S PROFILE



Mr Aristotle Ang

General Manager, Digital Advanced Technology Accelerator, Yong Loo Lin School of Medicine, National University of Singapore

Aristotle Ang is the General Manager of the NUS Medicine Digital Advanced Technology Accelerator, with over nine years of experience in healthcare business and operations. With a background in Biology and Biomedical Sciences, he began his career at Deloitte, exploring futuristic healthcare delivery models. He then moved to IHH Healthcare, focusing on business analytics and pricing across markets in Singapore, Malaysia, China, India, and Hong Kong. During COVID, he joined Tan Tock Seng Hospital, where he optimised operations through analytics and simulation across Emergency, Outpatient, Inpatient, Pharmacy and Visitor Experience settings, and also managed Advanced Analytics projects for the Command, Control and Communications (C3) system. At present, Aristotle brings his experience across both private and public healthcare to building a digital health startup accelerator at NUS Medicine, where he believes that supporting startups and fresh solutions is essential to address evolving healthcare needs across Singapore and the region.



PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1210 - 1220

SHARING BY FEM SURGERY

SPEAKER'S PROFILE



Ms Tiziana Tan

Director, MediXR

Tiziana is an entrepreneur and ecosystem builder with a passion for reimagining how innovation, design and storytelling create more human-centred systems. She is currently a Director at MediXR, a HealthTech venture group focused on preventive care, patient experience, and clinical impact. At MediXR, she supports overall strategy, partnerships and growth across its portfolio of ventures, such as VR Consent, an immersive platform that helps patients better understand medical procedures and make informed decisions about their care.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1350 – 1435

KEYNOTE LECTURE

Primum Non Nocere, Secundum Simulare: The imperatives of in silico evidence in the digital era

SYNOPSIS

In silico trials (ISTs) and computational medicine are poised to transform medical device development and regulation, embodying the principle of "Do No Harm by Design". This talk explores how ISTs can address the limitations of traditional clinical trials, including high costs, lengthy timelines, and safety concerns. By simulating device performance in virtual environments, ISTs offer a pathway to accelerate innovation, reduce expenses, and enhance patient safety. We'll examine compelling examples demonstrating ISTs' ability to replicate and extend traditional trial insights, tackling challenges like off-label use, device-dependent healthcare inequities, and optimal treatment stratification. Emphasising collaboration between regulators, industry, and patients, we'll discuss how ISTs can foster safer, more sustainable medical innovation.

SPEAKER'S PROFILE



Prof Alejandro F Frangi

Bicentenary Turing Chair in Computational Medicine
University of Manchester, Manchester, United Kingdom

Professor Alejandro Frangi FEng FIEEE holds the Bicentenary Turing Chair in Computational Medicine at the University of Manchester. As Director of the Christabel Pankhurst Institute, he accelerates health tech innovation translation in Greater Manchester. Prof Frangi is the Executive Director of the UK Centre of Excellence on In Silico Regulatory Science and Innovation, and leads the InSilicoUK Pro Innovation Regulations Network (www.insilicouk.org), advancing in silico medicine nationally. His research focuses on AI and in silico technologies, fostering collaboration between academia, industry, and regulators to drive healthcare innovation. He works at the intersection of computational modelling and medical science and aims to revolutionise patient care through cutting-edge technologies and interdisciplinary approaches. Prof Frangi is also committed to disseminating the benefits of in silico technologies to the lay audience through his recently launched podcast, In Silico Trials, Real Impacts (insilicouk.podbean.com).

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1435 – 1505

SESSION: ADVANCING HEALTH THROUGH DIGITAL INNOVATIONS

Use of AI Algorithm for Infant Growth Measurements

SYNOPSIS

The presentation highlights the shifting landscape of childhood malnutrition, where obesity is now as critical a concern as undernutrition. It emphasizes the importance of accurate growth monitoring during a child's first 1,000 days, with length and weight being key health indicators. However, the gold-standard method using length boards is often impractical and inaccurate. To address this, we developed the "growth tracker", an ai-powered tool using image recognition co-developed with KK women's and children's hospital in Singapore. Initial evaluation shows that growth tracker's accuracy is comparable to clinical measurements, and 97% of previously non-measuring parents are now willing to track growth monthly. The presentation also outlines deployment in Indonesia and Hong Kong.

SPEAKER'S PROFILE



Ms Agathe Foussat

Director of Digital Health, Danone Asia Pacific

Agathe has been working in digital innovation for more than 10 years from different locations including Europe, USA and Asia. New technologies to support consumers/patients and collect relevant data being her core expertise, she worked with big corporates and start-ups in diverse innovation hubs (Singapore and San Francisco) to build relevant and successful digital solutions. She is now the Digital Health Director for Danone in Singapore and brings digital health solutions in the market globally. Helping to make the invisible visible for consumers and patients via key health parameters tracking and health data collection to demonstrate nutrition benefits in Singapore and brings digital health solutions in the market globally. Helping to make the invisible visible for consumers and patients via key health parameters tracking and health data collection to demonstrate nutrition benefits.



PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1505 – 1535

SESSION: ADVANCING HEALTH THROUGH DIGITAL INNOVATIONS

Hyper-personalized Digital Twins for Early Pre-diabetes Interception

SYNOPSIS

We have constructed digital twins using anatomical and physiological circuits that faithfully and mechanistically describe the biological behaviour glucose homeostasis in the human body. In this presentation, we developed hyper-personalized, n-of-1 digital twins using wearable data such as continuous glucose monitoring (CGM) telemetry. We demonstrate how CGM data can be used to infer other blood-based biomarkers in space and time to obtain a holistic picture of an individual's glycemic control, and share findings from a clinical study demonstrating superior performance in prediabetes detection as compared with current gold standard clinical tests. Such advances can support Singapore's preventive and proactive health strategies through Healthier SG.

SPEAKER'S PROFILE



Dr James Chan

Deputy Head of Division, Nutrition & Digestive Health, Singapore Institute of Food and Biotechnology Innovation (SIFBI), A*STAR

Dr James Chan graduated with a Bachelor of Pharmacy degree and obtained his doctoral degree in Pharmaceutical Science from the National University of Singapore. Subsequently he joined A*STAR in 2018 and established an independent research group in 2020 at both the Singapore Institute of Food and Biotechnology Innovation (SIFBI) and the A*STAR Skin Research Labs (A*SRL). He is currently a Principal Investigator with extensive expertise in pharmacokinetic modelling. In particular, his team integrates digestibility profiles with in vitro absorption, distribution, metabolism and excretion measurements to predict the human pharmacokinetics of orally and topically ingested materials. His current research interests include developing human digital twins that allow prediction of the fate and behaviour of pharmaceutical, nutritional and consumer care compounds and extending these to the digital health space.

PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1605 – 1700

SESSION: INTRODUCTION TO MEDICAL DEVICES ECOSYSTEM IN SINGAPORE: MEDTECH CATAPULT & DIGITAL HEALTH ACCELERATOR INITIATIVES

Panel Discussion

SYNOPSIS

As global demand for innovative medical technologies accelerates, Singapore is emerging as a strategic hub for both advanced MedTech manufacturing and digital health innovation in Asia. This panel explores Singapore's comparative advantages—robust regulatory frameworks, world-class infrastructure, and deep R&D capabilities—while candidly addressing the challenges that must be overcome to scale up manufacturing excellence.

The discussion will spotlight:

How public-private partnerships, such as MedTech Catapult and DxHub, are catalyzing commercialization;

Regional collaboration opportunities through initiatives like the Singapore-Johor SEZ;

What drives global manufacturers like Cicor to invest in Singapore, and how Industry 4.0 technologies are reshaping production capabilities;

Regulatory nuances and incentives that make Singapore competitive globally for contract manufacturing.

Join us for an insightful conversation at the intersection of innovation, policy, and production—charting Singapore's trajectory as a next-generation MedTech and digital health hub.



PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1605 – 1700

SESSION: INTRODUCTION TO MEDICAL DEVICES ECOSYSTEM IN SINGAPORE: MEDTECH CATAPULT & DIGITAL HEALTH ACCELERATOR INITIATIVES

Panel Discussion

SPEAKERS' PROFILE

MODERATOR



Dr Gordon Xiong

Senior Assistant Director, Singapore Health Technologies Consortium
(HealthTEC.SG)

Dr. Gordon Xiong is the Senior Assistant Director of the Singapore Health Technologies Consortium (HealthTEC.SG). He has around 15 years of experience in R&D and managing innovation in health-related fields. In his current role, he oversees the planning and execution of the Consortium's ecosystem-building initiatives, including industry development, innovation partnerships and community-building events. Prior to his current role, he has worked as a researcher and laboratory manager in several disciplines of molecular biology and bioengineering and held the roles of co-investigator or theme lead of projects. He has published 30 peer-reviewed journal articles/reviews/book chapters and holds 3 patent applications, including one granted patent.

Passionate in contributing to the healthcare and biomedical engineering community, he currently serves as the Vice-President of the Biomedical Engineering Society (Singapore), as a Member of the Biomedical and Health Standards Committee (BHSC) of the Singapore Standards Council and is active in mentoring young entrepreneurs and global young fellows on innovation.



PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1605 – 1700

SESSION: INTRODUCTION TO MEDICAL DEVICES ECOSYSTEM IN SINGAPORE: MEDTECH CATAPULT & DIGITAL HEALTH ACCELERATOR INITIATIVES

Panel Discussion

PANELISTS



Mr Justin Phoon

Lead, Programme & Partnerships, MedTech Catapult

Justin has spent his career working in global medical device companies such as Medtronic, Zimmer, and Integer, where he focused on business development across areas like physical rehabilitation, neuromodulation, and orthopaedics. Through these roles, he has helped bring impactful technologies to market and built lasting relationships across the healthcare ecosystem.

Today, Justin leads Programme and Partnerships at MedTech Catapult, a national initiative that supports medical device innovators on the journey from prototype to product. By providing funding, expert guidance, and connecting product owners with design houses and local contract manufacturers, the team helps bring to life devices that solve real clinical needs. What motivates Justin is a deep belief in the power of medical technologies to improve patient outcomes and make a meaningful difference in healthcare.



PROGRAMME DETAILS

24 JUL 2025

24 JUL 2025 | 1605 – 1700

SESSION: INTRODUCTION TO MEDICAL DEVICES ECOSYSTEM IN SINGAPORE: MEDTECH CATAPULT & DIGITAL HEALTH ACCELERATOR INITIATIVES

Panel Discussion



Mr Lijoy George

Head of Digital Diagnostics, Lead of Digital Health Accelerator, DxD Hub

Mr Lijoy George, Head of Digital Diagnostics at DxD Hub and Lead of the Digital Health Accelerator, possesses 16 years of experience at Philips Singapore in Healthcare Informatics Operations for ASEAN. Mr George is certified in Lean, Six Sigma-Green Belt, and Project Management (PMP), with a background in IT, healthcare project management, and clinical workflow optimisation in Cardiology and Radiology Informatics. He holds a degree in Mathematics & Statistics, a Master's in Computer Applications, and a Master's in Business Administration.



Mr Edwyn Tan

Sales Director Asia, Cicor Group

Edwyn represents Cicor Group, a leading Swiss provider of advanced electronics manufacturing services (EMS) and MedTech-focused design and development solutions. Based in Singapore, he plays a key role in enabling global MedTech innovators to accelerate time-to-market through integrated design-to-scale manufacturing strategies. Edwyn brings deep insights into MedTech supply chains, regulatory-ready production, and the advantages of partnering with agile CDMOs in Asia.



PROGRAMME DETAILS

25 JUL 2025 MORNING

25 JUL 2025 | 1020 - 1030

WELCOME & OPENING REMARKS

SPEAKERS' PROFILE



Mr Chris Lee

Founder & CEO, VentureBlick

Chris Lee is a global healthcare leader, entrepreneur, and startup advisor with over 30 years of experience spanning the pharmaceutical and medtech sectors. He is the Founder & CEO of VentureBlick, a Go Global partner for healthcare innovation. Headquartered in Singapore with operations in Korea, India, and China, VentureBlick helps startups scale, supports SMEs with global expansion, and enables healthcare corporations to discover new technologies. Its curated network of over 6,500 clinicians and domain experts across 60+ countries ensures medical value stays at the heart of innovation.

Chris previously served as APAC President at both Medtronic and Bayer Healthcare, making him one of the few Asians to rise to the global executive committee level in two Fortune 500 healthcare companies. Born in Korea, he has worked across 10 countries and led high-impact initiatives in business growth, M&A, and market expansion.

He began his career as a medical sales rep in US, became country manager at 30, and made history as Bayer's first Asian executive committee member at age 39. Passionate about leadership and inclusion, Chris was named "Most Respected CEO" three years in a row and recently authored *The Asian Maverick*, sharing leadership lessons from an Asian perspective.



PROGRAMME DETAILS

25 JUL 2025 MORNING

25 JUL 2025 | 1020 - 1030

WELCOME & OPENING REMARKS



Dr Gordon Xiong

Senior Assistant Director, Singapore Health Technologies Consortium
(HealthTEC.SG)

Dr. Gordon Xiong is the Senior Assistant Director of the Singapore Health Technologies Consortium (HealthTEC.SG). He has around 15 years of experience in R&D and managing innovation in health-related fields. In his current role, he oversees the planning and execution of the Consortium's ecosystem-building initiatives, including industry development, innovation partnerships and community-building events. Prior to his current role, he has worked as a researcher and laboratory manager in several disciplines of molecular biology and bioengineering and held the roles of co-investigator or theme lead of projects. He has published 30 peer-reviewed journal articles/reviews/book chapters and holds 3 patent applications, including one granted patent.

Passionate in contributing to the healthcare and biomedical engineering community, he currently serves as the Vice-President of the Biomedical Engineering Society (Singapore), as a Member of the Biomedical and Health Standards Committee (BHSC) of the Singapore Standards Council and is active in mentoring young entrepreneurs and global young fellows on innovation.

PROGRAMME DETAILS

25 JUL 2025 AFTERNOON

25 JUL 2025 | 1430 – 1500

EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR

Sharing by SGInnovate

SPEAKER'S PROFILE



Dr Vanessa Ding

Deputy Director, Talent, SGInnovate

Dr Vanessa Ding is currently the Deputy Director of the Talent Team at SGInnovate. She leads the Helix Immersion Programme team to help build a pipeline of “work-ready” talent to bridge the gap for the Biotech ecosystem in Singapore.

She was trained as a Chemical Engineer at the University of Queensland, Australia. She later graduated with a PhD (Stem Cell Biology) from the National University of Singapore under the A*STAR Graduate Scholarship. During her postdoc at the Bioprocessing Technology Institute, Dr Vanessa co-led several antibody discovery programmes and cross-collaborated with industries/clinicians in the areas of ophthalmology and oncology indications (for both human and veterinary applications). She has filed seven patents on various novel monoclonal antibodies, with two granted to date. She played an instrumental role in the early-stage discovery and development team for EBC-129, the first made-in-Singapore antibody drug conjugate approved to enter clinical trials in the United States and Singapore.

Dr Vanessa has accumulated more than 16 years of experience spanning R&D in cell biology and therapeutics development, spinoff management, strategic planning, and commercial development in the biotech and the bioprocessing industry.

PROGRAMME DETAILS

25 JUL 2025 AFTERNOON

25 JUL 2025 | 1500 – 1530

EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR

Sharing by AstraZeneca

SPEAKER'S PROFILE



Mr Samuel Koh

Corporate Affairs Director, AstraZeneca Singapore

Samuel has led driving important corporate strategies which include establishing long-term growth of AstraZeneca Singapore as Corporate Affairs Director since 2020. He also has been coordinating legislative efforts by working with various government organizations through policy shaping and stakeholder management.

Samuel brings with him a wealth of commercial pharmaceutical experience, having held various leadership roles in sales, product management, market access, corporate affairs and communications at MSD Pharma in Singapore. In current capacity, he is Corporate Affairs Director and sits as a member of the Country Leadership Team and responsible for leading the external affairs function to oversee policy shaping, market access and communications initiatives for Singapore.

Samuel holds a Bachelor of Science in Biomedical Science (First Class Honours) from Murdoch University in Australia.

PROGRAMME DETAILS

25 JUL 2025 AFTERNOON

25 JUL 2025 | 1530 – 1600

EXPLORING THE SINGAPORE-SWEDEN INNOVATION CORRIDOR

Sharing by Enterprise Singapore

SPEAKER'S PROFILE



Mr Jerrold Chua

Senior Development Partner, Global Innovation Network, Enterprise Singapore

Jerrold oversees the Global Innovation Alliance (GIA) initiatives in Western Europe and the Nordics, supporting startups and enterprises to venture and scale in key demand markets. He manages strategic partnerships with in-market accelerators, innovation partners and government agencies to create business and R&D collaborations between Singapore and overseas enterprises.

PROGRAMME DETAILS

25 JUL 2025 AFTERNOON

25 JUL 2025 | 1600 – 1730

SAHLGRENKA GLOBAL HEALTH HACKATHON-SINGAPORE LEG

SPEAKER'S PROFILE



Ms Cecilia Edebo

CEO, Sahlgremska Science Park

Cecilia Edebo is today CEO at Sahlgremska Science Park. Until recently she was CEO of Cellink, which she was part of transforming from a unicorn start-up to a global market leader in 3D bioprinting, today part of BICO Group.

Cecilia has extensive experience within life science, having held several leading positions as CEO, COO and VP within Essity and SCA Hygiene Products, where she was part of growing and expanding the business across the globe, primarily in Europe and Asia (including Singapore). Cecilia brings extensive experience of both entrepreneurship and business management driving innovation within life science from startups and large MNCs, as well as an extensive network of scientific and business collaboration partners.

ACKNOWLEDGEMENTS

SPONSORS



Ascentia Consulting Executives (ACE) is a bespoke financial services firm dedicated to delivering customized corporate financial solutions for businesses.

With a strong focus on talent acquisition, risk management, and business continuity, ACE empowers organizations to succeed in today's competitive landscape.

Their core expertise includes asset management, employee benefit strategies, key man insurance, and executive bonus planning. ACE serves a wide range of industries—including healthcare, technology, medical, and engineering—through strategic partnerships and a client-first approach.



Thrive With Us

FeM Surgery is a future-forward surgical specialist group redefining private healthcare delivery through precision, personalization, and the power of multidisciplinary collaboration. With a foundation in evidence-based medicine, we integrate cutting-edge surgical practices with a patient-centric care model to serve both common and complex medical needs. At the core of FeM Surgery is a belief in partnering with patients, not just treating conditions. Our clinicians collaborate across specialties to deliver seamless, outcomes-driven care. This integrated approach empowers innovations in diagnostics, minimally invasive procedures, care coordination, and preventive screening.

We are a Singapore-based surgical specialist group practice with five outpatient clinics, a Day Surgery Centre, and a Wellness Centre, all anchored by board-certified specialists. What sets FeM Surgery apart isn't just clinical capability, it is how we integrate that with scalability and innovation.

(continued on next page)

ACKNOWLEDGEMENTS

SPONSORS

Our spectrum of care spans oncologic, endocrine, colorectal, hepatobiliary, breast, spine, urology, orthopaedic, vascular, and neurosurgical services, among others. Each centre functions as both a treatment hub and a fertile ground for deploying and testing health-tech integrations, including digital diagnostics, predictive analytics, and patient engagement tools.

If you're building solutions that intersect with surgical innovation, remote care enablement, or AI-enhanced clinical workflows, FeM Surgery offers a living ecosystem for scalable, tech-enabled care models. Our goal is to be more than a care provider, we want to be your clinical innovation partner. If you're looking for a credible, collaborative, and future-ready healthcare ally - FeM Surgery is ready.

For more information, please visit FeM Surgery website www.femsurgery.com

Any inquiries, email info@femsurgery.com

MEDI XR

Better Health: Earlier, Everyone, Everywhere

MediXR is a HealthTech venture group creating health innovations that start earlier, reach further, and serve better. We build and back ventures focused on preventive health, patient experience, and clinical impact — designed for the realities of today and the possibilities of tomorrow.

Our approach is grounded in clinical insight and driven by emerging technology. From digital consent and immersive education to mental wellbeing, lifestyle change, and ageing with dignity, MediXR supports the entire health journey.

Our first venture, MediXR: VR Consent, is transforming how patients engage with their care. Using 3D simulations and personalised guidance, it helps patients understand their procedures and give meaningful, informed consent.

MediXR was founded to rethink what's possible in healthcare; not just when people fall sick, but long before and well beyond.

ACKNOWLEDGEMENTS

SPONSORS



Experts for Medical Devices

qttec Services is your expert partner for navigating the full lifecycle of medical devices. With a team of nearly 100 dedicated specialists, we provide tailored services across all key stages — from Requirements Engineering and Risk Management to Software Quality, Clinical Evaluation, Regulatory Affairs (MDR), and Post-Market Surveillance.

Our interdisciplinary team collaborates closely with manufacturers to develop efficient, sustainable, and regulation-compliant solutions. Clients value our speed, deep experience, and hands-on support — enabling them to bring their innovations to market faster and more securely.

Headquartered in Germany, qttec Group delivers high-quality support for medical device companies across Europe and beyond.

Learn more at www.qttec-group.com



ASCENTIA CONSULTING EXECUTIVES

About Us

We are a bespoke financial services firm providing customized corporate financial solutions. We empower businesses in talent acquisition & retention, ensuring protection and business continuity in today's competitive landscape.

Our Mission

To tailor services to each organization's unique needs and objectives

To build strong partnerships with insurers and experts to deliver comprehensive & tailored financial solutions.

Industries We Serve

- ✓ Healthcare
- ✓ Technology
- ✓ Engineering
- ✓ Retail
- ✓ Manufacturing
- ✓ Medical

Contact Us
+65 8043 5840



Asset Management

Optimize and grow financial assets of your company



Key Man Insurance

Protect your business against the loss of essential personnel



Employees Benefit

Attract and retain talents with customised group medical benefits



Executive Bonuses

Reward your leadership team with long term benefits, eg. pensions or executive bonuses



Corporate workshops

Empower businesses with interesting financial and healthcare talks



Business Insurance

Comprehensive insurance solutions for all your business needs.



Experts for Medical Devices

The qtec Group GmbH is currently a team of 100 smart and closely networked experts who see themselves as partners for manufacturers of medical devices. The service we offer, correlates directly with the typical life cycle of a Medical Device.

It begins with Requirements Engineering and Risk Management, Software Quality, Verification and Validation, Clinical Evaluation, Registration, and continuing on to Post-Market Surveillance. Our team of experts is happy to support you and your company with the MDR and IVDR.

Why customers come to us:

Our customers trust us for good reason – because we offer tailor-made solutions for every challenge our customers may face. You can rely on our expertise and our experience to address your requests professionally and efficiently.

- » Speed: Projects that succeed quickly
- » Experience: We know the pressure you are under
- » Engagement: We offer in-depth support

The qtec Group and its divisions

Our company consists of four specialized divisions, which are tailored to the requirements of the respective fields.



qtec
services

More efficiency for
your approval

qtec
eurep

Access to the
European market

qtec
ce-med

We are your legal
manufacturer

qtec
academy

Knowledge expansion
with training courses



☎ Telefon: +49 451 80 85 03 60

✉ E-Mail: info@qtec-group.com

🌐 Web: www.qtec-group.com

Comprehensive Support for Medical Device Development and Market Access

Clinical Affairs

Demonstrating the clinical safety and performance of medical devices through expert-driven clinical evaluations and trials.

Design Control

Structured product development that ensures medical devices are safe, effective, and ready for manufacturing.

Quality Management

Efficient quality systems that reduce costs, minimize risks, and are essential for market access and compliance.

Regulatory Affairs

Guiding your medical device through global regulatory requirements—from conformity assessment to post-market surveillance.

Your Support for (EU) Medical Device Compliance - From Concept to Market and Post-Market Confidence.



Collaborate With Worldwide Tech Innovators



**Latest
News**



**Networking &
Events**



**Funding
Programme**



**Investment
Matching**



**Business
Matching**



**Soft-landing
Programme**



SCAN HERE
to subscribe

ACKNOWLEDGEMENTS

SUPPORTING PARTNERS



APACMed

The Asia Pacific Medical Technology Association (APACMed) represents manufacturers and suppliers of medical equipment, devices and in-vitro diagnostics, industry associations and other key stakeholders associated with the medical technology industry in Asia Pacific. As a trade association, our mission is to improve the standards of care for patients through innovative collaborations among stakeholders to jointly shape the future of healthcare in Asia Pacific.



AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca Singapore is one of Singapore's leading biopharmaceutical companies that aim to make a difference in the healthcare industry by touching and saving as many lives as we can through our innovation in the scientific medical field.



NUS Medicine Digital Advanced Technology Accelerator

At the NUS Medicine Digital Advanced Technology Accelerator, we are passionate about fostering the growth of young digital health start-ups across Asia. As an accelerator dedicated exclusively to healthcare, we focus on the unique challenges and opportunities in this sector. Our mission is to empower innovators to turn ideas into impactful healthcare solutions, nurture entrepreneurs building digital health ventures, and cultivate a collaborative ecosystem to accelerate healthcare transformation. By providing a platform for collaboration and innovation, we believe we can inspire bright minds to develop solutions that make a meaningful difference in global healthcare.

ACKNOWLEDGEMENTS

SUPPORTING PARTNERS



Hong Kong Science and Technology Parks Corporation

Innovation and technology run in our DNA. From Hong Kong to the world, we are propelling pioneers into forces for good, steering them to success, and transforming their ideas into impact. For 20 years, we have been building up Hong Kong as an international I&T hub, creating a thriving ecosystem with our world-class infrastructure, collaborative network, and global vision.

We are here to spark innovation that empowers future generations. From Hong Kong's largest R&D base, entrepreneurs and companies can flourish in our four future-ready focus areas, namely AI & Robotics, Data & Smart City, Biomedical Technology, and Fintech. A launchpad for international ambitions, our innovation hive offers programmes for incubating great ideas and commercialising technologies.

Wherever they are in their journey, every tech talent can find a place to shine at our innovation campuses. From our key locations at the Hong Kong Science Park, the fintech-driven InnoCentre, the three modern IINNOPARKs in Tai Po, Tseung Kwan O and Yuen Long, and the Hong Kong-Shenzhen Innovation & Technology Park, we are re-imagining a future that is better, brighter, and smarter.



IPI

IPI is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries.

As a subsidiary of Enterprise Singapore, IPI accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.

IPI believes that innovation is key to enterprise growth and provides enterprises with access to innovative ideas and technologies. We also facilitate and support enterprises' innovation processes, including commercialisation and go-to-market strategies.

(continued on next page)

ACKNOWLEDGEMENTS

SUPPORTING PARTNERS

With a multidisciplinary team and a broad network of global and local partners, IPI assists enterprises in sourcing relevant technologies, expertise, and collaborators. This helps enterprises to overcome innovation challenges and achieve accelerated growth.

IPI's services range from technology scouting and landscape studies to innovation challenges and Innovation Advisory, which offers customised coaching and insights from industry veterans.

IPI serves a wide spectrum of industries and partners, fostering a collaborative environment that drives technological advancements and enterprise growth. By leveraging its extensive network and deep expertise, IPI continues to empower enterprises to innovate and expand, ultimately contributing to a more dynamic and robust innovation ecosystem.



MedTech Catapult

MedTech Catapult (MC) is a national initiative hosted by the Agency for Science, Technology and Research (A*STAR) that seeks to establish itself as the go-to medical device product development platform in Singapore.

MC operates to bolster local design and development capabilities for novel MedTech product development whilst enhancing

high-value MedTech manufacturing capacities of our local contract manufacturing organisations (CMOs). Through this, we will contribute to the growth of an innovation-driven economy and a robust MedTech ecosystem in Singapore.

MC offers comprehensive support including in-house product engineering, quality assurance, regulatory affairs, clinical affairs, as well as project management to accelerate market readiness. By collaborating with clinicians, regulators, and industry leaders, we guide product owners of life science instruments and medical devices through the development cycle, aiming for manufacturing in Singapore.

ACKNOWLEDGEMENTS

SUPPORTING PARTNERS



NUS iHealthtech

The Institute for Health Innovation & Technology (iHealthtech) at NUS, established in 2017, focuses on addressing clinical challenges through innovative health technologies. By fostering interdisciplinary collaboration across engineering, medicine, computing, and science, as well as partnerships with industry, iHealthtech aims to translate lab discoveries into clinical and market-ready solutions. The institute's research spans Precision Diagnostics, Smart Sensors, Artificial Intelligence, and Novel Therapeutics, all geared towards improving disease diagnosis, monitoring, and treatment. To support this mission, iHealthtech established the Healthtech Translation Hub (HATCH), a dedicated unit that helps researchers bring health innovations from bench to bedside.



SGInnovate

SGInnovate is a Deep Tech ecosystem builder and investor, backed by the Singapore Government. Our expertise and approach combines investments, talent development and community-building to catalyse the translation of emerging technologies into tomorrow's opportunities.

Through our flagship Deep Tech Central platform, we connect individuals, founders and companies to specialised resources and opportunities across all technological domains and stages of growth. Our portfolio of emerging tech startups comprises some of the most promising companies leading the commercialisation of research developed from Singapore's RIE ecosystem.

Connect with us at [SGInnovate.com](https://www.sginnovate.com).



VentureBlick

VentureBlick is the one-stop Go Global solution for healthcare innovation, making cross-border cross-sector connections to take local innovations worldwide. We unite innovators, clinicians, investors, and ecosystem partners on a global scale for better visibility and efficiency. Headquartered in Singapore, we also operate in several other markets including Korea, Germany, India, and China. Learn more at www.ventureblick.com.

ACKNOWLEDGEMENTS

ECOSYSTEM PARTNERS



MedTech Actuator

The MedTech Actuator is Asia Pacific's MedTech catalyst – We set a new global standard for medical technology commercialisation acceleration. Our programs deploys a dynamic, integrated program that supports rapid transformation of new ideas into solutions that change the face of global healthcare.



MedTech Innovator Asia Pacific

MedTech Innovator Asia Pacific is the leading nonprofit accelerator for medical device, digital health, and diagnostic startups in the region. Launched in 2019, it connects high-potential startups with key industry partners, investors, and regional stakeholders.

Each year, 20 top startups are selected for a high-impact program offering mentorship, strategic exposure, and up to USD 300,000 in non-dilutive funding and other awards. Part of the world's largest medtech accelerator, our mission is to improve patient lives by helping startups bring innovative solutions to accelerate.



Singapore Biodesign

Singapore Biodesign, a National-level talent development platform and global affiliate of the renowned Stanford Mussallem Center for Biodesign, focuses on bringing economic benefits and healthcare value through its healthtech innovation training. The programme aims to empower the next generation of med-/healthtech innovators for Asia using the needs-centric Biodesign Process that the programme has adapted for the region.



**INTERNATIONAL
HEALTHTEC
SUMMIT 2025**

Organised by



Sponsors



Supporting Partners



Ecosystem Partners



Accelerating health tech innovations through collaborations

Singapore Health Technologies Consortium (HealthTEC.SG),
Consortium Management Office (CMO)
@Agency for Science, Technology and Research (A*STAR)

www.healthtec.sg
contact@healthtec.sg

1 Fusionopolis Way Level 14 Connexis North Building Singapore 138632